-
Mashup Score: 1
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2An overview of EHA guidelines for the use of antifungal prophylactic agents in acute myeloid leukemia - 2 year(s) ago
With increasing diversity of advances in the treatment of acute myeloid leukemia (AML), the need for prophylaxis against infection has also evolved. Triazoles currently serve as the cornerstone antifungal agent during remission reduction chemotherapy treatment of AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ELARA trial: Does tisa-cel CAR T-cell therapy hold promise for patients with follicular lymphoma? - 2 year(s) ago
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-UniversitΓ€t MΓΌnchen, Munich, DE. We asked, Does tisa-cel chimeric antigen receptor (CAR) T-cell therapy hold promise for patients with follicular lymphoma?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHL - 2 year(s) ago
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Martin Hutchings, Rigshospitalet, Copenhagen, DK. We asked, What are the updated results of brentuximab vedotin + chemotherapy for untreated classical Hodgkin lymphoma (cHL)?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Should pre-transplant MRD be used to guide treatment in AML? - 2 year(s) ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0How does COVID-19 affect outcomes in AML? - 2 year(s) ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Olga Gavrilina, National Research Center for Hematology, Moscow, RU. We asked, How does COVID-19 affect outcomes in AML?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Should antifungal prophylaxis be used in patients with AML who are treated with novel agents? - 2 year(s) ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Jannik Stemler, University Hospital Cologne, Cologne, DE. We asked, Should antifungal prophylaxis be used in patients with AML who are treated with novel agents?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Which R/R AML subgroups would benefit from enasidenib treatment? - 2 year(s) ago
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, Which relapsed/refractory AML subgroups would benefit from enasidenib treatment?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory AML treatment with venetoclax and hypomethylating agents (HMAs)?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
β° Catch up with this! During #EHA2021, the Lymphoma Hub spoke with @gilles_salles, @sloan_kettering. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma? π https://t.co/Oqv4ZRKP8T π #lymsm #lymphoma https://t.co/oeNZhzWRLK